{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:12:47Z","timestamp":1792033967090,"version":"4.4.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.ejmech.2018.05.017","type":"journal-article","created":{"date-parts":[[2018,5,14]],"date-time":"2018-05-14T02:00:17Z","timestamp":1526263217000},"page":"110-116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Synthesis of proline derived benzenesulfonamides: A potent anti- Trypanosoma brucei gambiense agent"],"prefix":"10.1016","volume":"154","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2370-6191","authenticated-orcid":false,"given":"David I.","family":"Ugwu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uchechukwu C.","family":"Okoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narendra K.","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2018.05.017_bib1","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0140-6736(09)60829-1","article-title":"Human african trypanosomiasis","volume":"375","author":"Brun","year":"2010","journal-title":"Lancet"},{"issue":"5733","key":"10.1016\/j.ejmech.2018.05.017_bib2","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1126\/science.1112642","article-title":"The genome of the African trypanosome Trypanosoma brucei","volume":"309","author":"Berriman","year":"2005","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.ejmech.2018.05.017_bib3","first-page":"1474","article-title":"Treatment of human african trypanosomiasis","volume":"78","author":"Dumas","year":"2000","journal-title":"Bull. World Health Organ."},{"issue":"2","key":"10.1016\/j.ejmech.2018.05.017_bib4","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-3156.2007.01999.x","article-title":"Eflornitine is a cost-effective alternative to melarsoprol for the treatment of second-stage human west African trypanosomiasis in Caxito, Angola","volume":"13","author":"Robays","year":"2008","journal-title":"Trop. Med. Int. Health"},{"issue":"3","key":"10.1016\/j.ejmech.2018.05.017_bib5","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/0924-8579(94)90012-4","article-title":"Drugs used in the treatment of sleeping sickness","volume":"4","author":"Wery","year":"1994","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejmech.2018.05.017_bib6","first-page":"708","article-title":"Safety and effectiveness of first line eflornithine for Trypanosoma brucei gambiense sleeping sickness in Sudan: cohort study","volume":"336","author":"Priotto","year":"2010","journal-title":"Br. Med. J."},{"key":"10.1016\/j.ejmech.2018.05.017_bib7","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1046\/j.1365-3156.2001.00710.x","article-title":"Clinical description of encephalopathic syndromes and risk factors for their occurrence and outcome during melarsoprol treatment of human African trypanosomiasis","volume":"6","author":"Blum","year":"2001","journal-title":"Trop. Med. Int. Health"},{"issue":"2","key":"10.1016\/j.ejmech.2018.05.017_bib8","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1093\/cid\/cis886","article-title":"Nifurtimox-eflornithine combination therapy for second-stage gambiense human african trypanosomiasis: m\u00e9decins sans fronti\u00e8res experience in the democratic republic of the Congo","volume":"56","author":"Alirol","year":"2013","journal-title":"Clin. Infect. Dis."},{"issue":"5","key":"10.1016\/j.ejmech.2018.05.017_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000720","article-title":"NECT is next: implementing the new drug combination therapy for Trypanosoma brucei gambiense sleeping sickness","volume":"4","author":"Yun","year":"2010","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ejmech.2018.05.017_bib10","first-page":"344","article-title":"Synthsis, docking and in\u00a0vitro activity of thisemicarbazones and acyl-thiazolidones against trypanosoma cruzi","volume":"2","author":"Leite","year":"2014","journal-title":"Soc. Bras. Quim."},{"issue":"9","key":"10.1016\/j.ejmech.2018.05.017_bib11","doi-asserted-by":"crossref","first-page":"3703","DOI":"10.1016\/j.ejmech.2011.05.035","article-title":"Synthesis, trypanocidal activity and. molecular modeling studies of 2-alkylaminomethylquinoline derivatives","volume":"46","author":"Muscia","year":"2011","journal-title":"Eur. J. Med. Chem."},{"issue":"11","key":"10.1016\/j.ejmech.2018.05.017_bib12","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1021\/jm300508n","article-title":"Novel 3-Nitro-1H-1,2,4-triazole-Based amides and sulfonamides as potential antitrypanosomal agents","volume":"55","author":"Papadopoulou","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"issue":"10","key":"10.1016\/j.ejmech.2018.05.017_bib13","first-page":"1884","article-title":"Synthesis and in\u00a0vitro evaluation of novel glactosyl-triazolo-benzenesulfonamides against trypanossoma cruzi","volume":"25","author":"Junqueira","year":"2014","journal-title":"J.\u00a0Braz. Chem. Soc."},{"issue":"23","key":"10.1016\/j.ejmech.2018.05.017_bib14","doi-asserted-by":"crossref","first-page":"9869","DOI":"10.1021\/jm500809c","article-title":"Lead optimization of a pyrazole sulfonamide series of Trypanosoma brucei N-myristoyltransferase inhibitors: identification and evaluation of CNS penetrant compounds as potential treatments for stage 2 human African trypanosomiasis","volume":"57","author":"Brand","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.05.017_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001896","article-title":"Identification of compounds with anti-proliferative activity against Trypanosoma brucei brucei strain 427 by a whole cell viability based HTS campaign","volume":"6","author":"Sykes","year":"2012","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ejmech.2018.05.017_bib16","unstructured":"D.G. Kulman, R. Lama, B. Li, B. Su, Cleveland State University www.csuohio.edu\/sites\/default\/files\/29-%202015.pdf retrieved on 22nd February 22, 2017."},{"issue":"7","key":"10.1016\/j.ejmech.2018.05.017_bib17","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1021\/jm0304461","article-title":"Synthesis and antitubulin activity of N1- and N4-substituted 3,5-dinitro sulfanilamides against African trypanosomes and Leishmania","volume":"47","author":"Bhattacharya","year":"2004","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.05.017_bib18","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ejmech.2016.04.065","article-title":"Design, synthesis and antitrypanosomal activity of some nitrofurazone 1,2,4-triazolic bioisosteric analogues","volume":"121","author":"Silva","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.05.017_bib19","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ejmech.2016.04.010","article-title":"Antitrypanosomal activity of 5-nitro-2-aminothiazole-based compounds","volume":"117","author":"Papadopoulou","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.05.017_bib20","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1016\/j.bmc.2011.01.010","article-title":"Synthesis and biological evaluation of 1,4-benzodiazepin-2-ones with antitrypanosomal activity","volume":"19","author":"Spencer","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.05.017_bib21","series-title":"Inflammation May Be Link between Extreme Sleep Duration & Poor Health","author":"American Academy of Sleep Medicine","year":"2009"},{"issue":"7","key":"10.1016\/j.ejmech.2018.05.017_bib22","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1080\/00397911.2014.984853","article-title":"Direct waste-free synthesis of amides from nonactivated carboxylic acids and amines: application to the synthesis of tetrahydroisoquinolines","volume":"45","author":"Bala","year":"2015","journal-title":"Synth. Commun."},{"key":"10.1016\/j.ejmech.2018.05.017_bib23","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1021\/op700098w","article-title":"Boric acid catalysed amidation in the synthesis of active pharmaceutical ingredients","volume":"11","author":"Mylavarapu","year":"2007","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/j.ejmech.2018.05.017_bib24","doi-asserted-by":"crossref","first-page":"262","DOI":"10.15227\/orgsyn.081.0262","article-title":"Boric acid catalyzed amide formation from carboxylic acids and amines","volume":"81","author":"Tang","year":"2005","journal-title":"Org. Synth."},{"key":"10.1016\/j.ejmech.2018.05.017_bib25","doi-asserted-by":"crossref","first-page":"4523","DOI":"10.1021\/jo400509n","article-title":"T.D.Sheppard, direct synthesis of amides from carboxylic acids and amines using B(OCH2CF3)3","volume":"78","author":"Lanigan","year":"2013","journal-title":"J.\u00a0Org. Chem."},{"key":"10.1016\/j.ejmech.2018.05.017_bib26","first-page":"31","article-title":"Lipophilicity indices for drug development","volume":"1","author":"Arnott","year":"2013","journal-title":"J.\u00a0Appl. Biopharm. Pharmacokinet."},{"key":"10.1016\/j.ejmech.2018.05.017_bib27","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1007\/s11095-010-0303-7","article-title":"Lipophilicity and its relationship with passive drug permeation","volume":"28","author":"Liu","year":"2011","journal-title":"Pharmaceut. Res."},{"key":"10.1016\/j.ejmech.2018.05.017_bib28","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1023\/A:1020444330011","article-title":"Rate-limited steps of human oral absorption and QSAR studies","volume":"19","author":"Zhao","year":"2002","journal-title":"Pharmaceut. Res."},{"key":"10.1016\/j.ejmech.2018.05.017_bib29","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ejmech.2017.04.029","article-title":"Synthesis, characterization, molecular docking and in\u00a0vitro antimalarial properties of new carboxamides bearing sulphonamide","volume":"135","author":"Ugwu","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.05.017_bib30","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/ja.2008.52","article-title":"Selective and potent in\u00a0vitro antitrypanosomal activities of ten. microbial metabolites","volume":"61","author":"Otoguro","year":"2008","journal-title":"J.\u00a0Antibiot."},{"key":"10.1016\/j.ejmech.2018.05.017_bib31","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1002\/j.1460-2075.1985.tb03772.x","article-title":"Cultivation in a semi-defined medium of animal infective forms of Trypanosoma brucei, T. equiperdum, T. evansi, T. rhodesiense and T. Gambiense","volume":"4","author":"Baltz","year":"1985","journal-title":"EMBO J."},{"issue":"2","key":"10.1016\/j.ejmech.2018.05.017_bib32","first-page":"280","article-title":"Synthesis, characterisation and biological evaluation of novel coumarin derivatives","volume":"3","author":"Selvam","year":"2010","journal-title":"Rasayan J. Chem."},{"key":"10.1016\/j.ejmech.2018.05.017_bib33","series-title":"Fundamentals of Experimental Pharmacology Scientific Book Agency, Calcutta","first-page":"153","author":"Ghosh","year":"1984"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523418304215?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523418304215?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T20:15:13Z","timestamp":1571343313000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523418304215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":33,"alternative-id":["S0223523418304215"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2018.05.017","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis of proline derived benzenesulfonamides: A potent anti-Trypanosoma brucei gambiense agent","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2018.05.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}